Seattle, WA, United States

VentiRx Pharmaceuticals

www.ventirx.com
Seattle, WA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
VentiRx Pharmaceuticals and University of Pennsylvania | Date: 2017-07-26

The present invention is directed generally to formulations of a TLR agonist preferably a TLR8 agonist, and its use in the treatment of various diseases, including combination therapies for treating cancer.


Patent
VentiRx Pharmaceuticals and Array BioPharma | Date: 2017-08-23

Provided are compounds of formula (II) useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compounds have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.


Patent
VentiRx Pharmaceuticals and Array BioPharma | Date: 2017-08-23

Provided are benzazepine derivatives useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The benzazepine derivatives have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.


Patent
VentiRx Pharmaceuticals | Date: 2016-10-11

The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.


Patent
VentiRx Pharmaceuticals and Array BioPharma | Date: 2017-04-26

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.


Patent
VentiRx Pharmaceuticals and Array BioPharma | Date: 2015-11-04

The disclosure describes method of synthesis of substituted benzazepine derivatives. Preferred methods according to the disclosure allow for large-scale preparation of benzazepine compounds having low levels of metal impurities. In some embodiments, preferred methods according to the disclosure also allow for the preparation of benzazepine derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. The methods disclosed herein find utility in synthetic organic chemistry as well as medicinal chemistry.


Patent
Array BioPharma and VentiRx Pharmaceuticals | Date: 2014-02-14

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.


Patent
VentiRx Pharmaceuticals and Array BioPharma | Date: 2015-08-04

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.


Patent
VentiRx Pharmaceuticals and Array BioPharma | Date: 2015-10-13

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.


Patent
VentiRx Pharmaceuticals | Date: 2015-12-21

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.

Loading VentiRx Pharmaceuticals collaborators
Loading VentiRx Pharmaceuticals collaborators